Click the play button for the audio version of this Research Summary
The world’s first clinical trial using iPS cells in Parkinson’s disease
Why is it important?
- Novelty 90% 90%
- Proximity 85% 85%
- Deliverability 80% 80%
More recently, new, renewable sources of tissue that can be grown into dopaminergic progenitor cells and eventually into dopamine neurons are gaining prominence: human pleuripotent stem cells (hPSCs) can be derived from early pre-implantation embryos (ESCs) or reprogrammed adult somatic cells (iPSCs).
The first human clinical trials within this consortium are scheduled to begin this year (2018). Indeed, the world’s first clinical trial using iPS cells in Parkinson’s disease will be beginning in a few weeks’ time in coordination with Kyoto University Hospital, following a recent press release (see link).